{'fraction_non_alphanumeric': 0.04234972677595628, 'fraction_numerical': 0.04781420765027322, 'mean_word_length': 4.937837837837838, 'pattern_counts': {'":': 0, '<': 5, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
PP.21.06: THE ADDITIONAL ANTIHYPERTENSIVE EFFECT OF STATINS IN HYPERTENSIVE PATIENTS WITH MODERATE RISK

Objective: According to 2013 ESH guidelines early combination antihypertensive therapy is recommended in pts with moderate risk if monotherapy does not provide achievement of blood pressure (BP) goals. We suggested that addition of statins, which are known for their BP lowering effect, to monotherapy of hypertensive pts with dislipidemia, would provide the effect of combination antihypertensive therapy. Design and method: 148 hypertensive males aged 40–55 with systolic BP within 140–179 mmHg and diastolic BP 90–109 mmHg, low-density cholesterol > 3,5 mmol/l and one additional risk factor (smoking, obesity) without signs of atherosclerotic disease not achieving BP goals (<140/90 mmHg) during one month healthy life-style changes were included in the trial. They were randomly divided in two groups by 74 pts in each. In the first group (main group) pts were placed on antihypertensive monotherapy and l0 mg of rosuvastatin. In the second group (reference group) pts received antihypertensive monotherapy combined with healthy life-style changes. The duration of trial was 3 months. Results: In the main group systolic BP decreased by 27,2mmHg (from 163,4 mmHg to 136,2 mmHg). In the reference group systolic BP decreased by 19,1 mmHg(from 162,8 mmHg to 143,7 mmHg), p < 0,005. The decrease of diastolic BP in the main group was 14,2 mmHg (from 102,4 mmHg to 88,2 mmHg). In the reference group the decrease of diastolic BP was 8,4 mmHg (from 101,9 mmHg to 93,5 mmHg), p < 0,005. As a result, the achievement of BP goals (< 140/90 mmHg) by the end of the study was significantly higher in the main group compared with the reference group – correspondingly 70,2% (52 pts) and 51,3%(38 pts), p < 0,005. Conclusions: Results show, that statins can provide additional lowering of BP in hypertensive pts with moderate risk treated with one drug. So, at least in hypertensive pts with dislipidemia the addition of statins to antihypertensive monotherapy could provide the achievement of BP in the majority of pts. So there will be no need to switch to combination antihypertensive treatment.